Abstract
The present study defines the function of NFATC1 and NFATC2 in osteoblast function in vivo and in vitro. Nfatc1loxP/loxP, Nfatc2loxP/loxP and Nfatc1loxP/loxP;Nfatc2loxP/loxP conditional mice were mated with BGLAP-Cre transgenics to inactivate Nfatc1 and Nfatc2 singly and in combination in osteoblasts. Microcomputed tomography demonstrated that male and female conditionally inactivated Nfatc1, Nfatc2 and dual Nfatc1;Nfatc2 mice had osteopenia at Lumbar 3 (L3) sites when compared to littermate controls. However, the Nfatc1 and Nfatc2 inactivation singly and in combination in Bglap-expressing osteoblasts did not result in an appreciable phenotype at femoral sites. Bone histomorphometry of L3 confirmed the osteopenic phenotype and demonstrated that Nfatc1;Nfatc2 inactivated male mice had a significant decrease in osteoblast number and in osteoblast surface and osteoid surface The dual downregulation of Nfatc1 and Nfatc2 in bone marrow stromal cells caused a decrease in Alpl and Bglap expression, confirming a role of these transcription factors in osteoblast function.
In conclusion, our studies reveal that NFATc1 and NFATc2 are necessary for optimal vertebral, but not femoral, bone homeostasis in vivo and osteoblast differentiation in vitro.
Keywords: NFATc2, bone formation, bone remodeling, osteoblasts
INTRODUCTION
The fate and the function of cells of the osteoblast lineage becomes defined by transcription factors acting in concert so that cellular maturity is reached and the cells acquire the function and properties of osteoblasts (Bianco & Gehron, 2000). Nuclear factor of activated T cells (NFAT) are intracellular proteins (NFATc1 to c4 and NFAT5) critical for a normal immune response and known to regulate cell differentiation in various lineages (Crabtree & Olson, 2002; Graef, Chen, & Crabtree, 2001; Sitara & Aliprantis, 2010). Therefore, NFATs regulate cellular events in immune and non-immune cells including cells residing in the bone environment.
NFATc1, c2, c3 and c4 are synthesized by skeletal cells, and NFATc1 has been recognized as one essential factor in the differentiation of myeloid cells toward mature osteoclasts (Aliprantis et al., 2008; Ikeda et al., 2006; Ikeda et al., 2004; Ishida et al., 2002; Matsuo et al., 2004; Takayanagi et al., 2002). Indeed, Nfatc1 deficient mice are osteopetrotic due to a lack of bone resorbing cells (Aliprantis et al., 2008). NFATc2 plays a less apparent role in the differentiation and function of osteoclasts (Ikeda et al., 2006; Ranger et al., 1998). The expression of a constitutively active form of NFATc2 (caNFATc2) directed by the Acp5 gene induces osteoclast formation and as a consequence promotes the resorption of bone (Ikeda et al., 2006). The deletion Nfatc2 in the myeloid lineage results in a decrease in osteoclastogenesis in vitro, but the deletion of Nfatc2 in myeloid cells does not result in skeletal manifestations in vivo and results from the global downregulation of Nfatc2 have been conflicting (Asagiri et al., 2005; Bauer et al., 2011; Yu, Zanotti, Schilling, & Canalis, 2018).
The role of NFATs in the differentiation of osteoblasts and the formation of bone is not as clearly established as their function in osteoclastogenesis and bone resorption. In vitro, expression of either caNFATc1 or caNFATc2 inhibits osteoblastogenesis (Zanotti, Smerdel-Ramoya, & Canalis, 2011, 2013). Accordingly, production of caNFATc2 in Col1a1-expressing osteoblasts causes osteopenia because of decreased osteoblastogenesis (Zanotti & Canalis, 2015). NFATs are activated following the dephosphorylation of serine residues by calcineurin, a phosphatase, and as a consequence NFATs translocate from the cytoplasm to the nucleus (Chow, Hou, & Bendeck, 2008; Hogan, Chen, Nardone, & Rao, 2003; Okamura et al., 2000). Studies in mouse models of calcineurin activation or inactivation in osteoblasts yielded conflicting outcomes so that the function of NFATs in osteoblast function and bone formation is not clearly defined (Sun et al., 2005; Yeo et al., 2007).
Murine models of Nfatc1 and Nfatc2 inactivation have demonstrated an inhibitory function of NFATs on chondrogenesis, and NFATs restrict osteochondroma formation both indicative of a role in chondrogenic cells (Ge et al., 2016; Ranger et al., 2000). However, in vivo models of Nfatc1 and Nfatc2 inactivation have not been used to establish the function of these transcription regulators in osteoblasts.
The purpose of the work being presented is to establish the contributions of NFATc1 and NFATc2, singly and in combination, to the differentiation and function of osteoblasts. To this end, we obtained Nfatc1loxP/loxP and utilized Nfatc2loxP/loxP conditional mice recently created by our group (Aliprantis et al., 2008; Yu et al., 2018). Nfatc1 and Nfatc2 were downregulated by Cre recombination under the control of BGLAP, which encodes osteocalcin, using a transgenic model previously reported to inactivate calcineurin in osteoblasts (Yeo et al., 2007; Zhang et al., 2002). The skeletal phenotype of conditional Nfatc1, Nfatc2 and dual Nfatc1;Nfatc2 null mice was examined by microcomputed tomography (μCT) of vertebral and femoral bones. In addition, the consequences of the Nfatc1 and Nfatc2 inactivation on osteoblast differentiation were determined in vitro.
MATERIALS AND METHODS
Nfatc1 and Nfatc2 Conditional and Cre-driver Mice
Nfatc2 conditional mice created in this laboratory were described previously and were backcrossed into a C57BL/6J background for ≥7 generations following the removal of the PGK-neo selection cassette as described (Yu et al., 2018). In this model, exon 2, which codes for the regulatory domain of NFATc2, is flanked by loxP sites and is removed by Cre recombination. This leads to a frame shift and the creation of a termination codon in exon 3, and the mature protein is devoid of regulatory and DNA binding domains (Okamura et al., 2000). Nfatc1 conditional mice, where loxP sites flank exon 3 of Nfatc1, were obtained from L. Glimcher and studied in a C57BL/6J background (Boston, MA) (Aliprantis et al., 2008).
BGLAP-Cre mice in a C57BL/6J background (Jackson Laboratory, Stock 019509), were used to inactivate Nfatc1, Nfatc2 or both in mature osteoblasts (Zhang et al., 2002). To inactivate Nfatc1, Nfatc2 or both, mice homozygous for Nfatc1loxP/loxP, Nfatc2loxP/loxP or Nfatc1loxP/loxP;Nfatc2loxP/loxP alleles and heterozygous for the BGLAP-Cre allele were bred with Nfatc1loxP/loxP, Nfatc2loxP/loxP or Nfatc1loxP/loxP;Nfatc2loxP/loxP mice, respectively. As a result, BGLAP-Cre;Nfatc1Δ/Δ, BGLAP-Cre;Nfatc2Δ/Δ and BGLAP-Cre;Nfatc1Δ/Δ;Nfatc2Δ/Δ and Nfatc1loxP/loxP, Nfatc2loxP/loxP and Nfatc1loxP/loxP;Nfatc2loxP/loxP control littermates were created.
Conditionally deleted mice were compared to littermate controls of the same sex and genetic composition. Genotyping of BGLAP-Cre, Nfatc1loxP and Nfatc2loxP alleles was performed by polymerase chain reaction (PCR) in DNA extracts obtained from mouse tails (Table 1). Cre-dependent recombination of loxP flanked sequences was documented by PCR in DNA extracted from tibiae or calvariae. All animal experiments were approved by the Animal Care and Use Committee of either Saint Francis Hospital and Medical Center or the University of Connecticut Health Center.
Table 1.
Allele | Strand | Sequence | Amplicon Size (bp) |
---|---|---|---|
BGLAP-Cre transgene | Forward Reverse |
5’-CAAATAGCCCTGCAGAT-3’ 5’-TGATACAAGGGACATCTTCC-3’ |
300 |
Nfatc1loxP | Forward Reverse |
5’-GGACAGTCTAAGGCCTGCTG-3’ 5’-ACCCCACATCCCAGAGTGA-3’ |
Nfatc1WT = 215 Nfatc1loxP = 300 |
Nfatc2loxP | Forward Reverse |
5’-GGTGTCTCCCTCAAATGTTCA-3’ 5’-GCGAATATGAGGACCCAAGT-3’ |
Nfatc2WT = 160 Nfatc2loxP= 250 |
LoxP recombination of Nfatc1loxP | Forward Forward Reverse |
5’-AAGGAATTACTGGGAAGCCTGGCA-3’ 5’-AGGGACTATCATTTGGCAGGGACA-3’ 5’-ACAGGAAACAGCTCTGTTCCACAC-3’ |
Recombined = 510 (Nfatc1Δ) Not recombined = 410 (Nfatc1loxP) |
LoxP recombination of Nfatc2loxP | Forward Reverse |
5’-AGCACAATGCCCATGTTCAC-3’ 5’-GGTGTCTCCCTCAAATGTTCA-3’ |
Recombined = 358 (Nfatc2Δ) Not recombined = 2342 (Nfatc2loxP) |
Gene | Strand | Primer Sequence | GenBank Accession Number |
---|---|---|---|
Alp1 | Forward Reverse |
5’-CGGTTAGGGCGTCTCCACAGTAAC[FAM]G-3’ 5’-CTTGGAGAGGGCCACAAAGG-3’ |
NM_007431 |
Bglap | Forward Reverse |
5’-GACTCCGGCGCTACCTTGGGTAAG-3’ 5’-CCCAGCACAACTCCTCCCTA-3’ |
NM_001037939 |
Nfatc1 | Forward Reverse |
5’-GCGCAAGTACAGTCTCAATGGCC-3’ 5’-GGATGGTGTGGGTGAGTGGT-3’ |
NM_198429; NM_001164110; NM_001164111; NM_001164112; NM_00116641091; NM_016791 |
Nfatc2 | Forward Reverse |
5’-AGAACAACATGAGAGCCACCATC-3’ 5’-AGCTCGATGTCAGCGTTTCG-3’ |
NM_010899 |
Rpl38 | Forward Reverse |
5’-AGAACAAGGATAATGTGAAGTTCAAGGTTC-3’ 5’-CTGCTTCAGCTTCTCTGCCTTT-3’ |
NM_001048057; NM_001048058; NM_023372 |
Microcomputed Tomography
Femoral and vertebral (L3) microarchitecture was defined using a μCT40 microcomputed tomography instrument (Scanco Medical AG, Basserdorf, Switzerland). Calibration was performed weekly using a manufacturer-provided phantom (Bouxsein et al., 2010; Glatt, Canalis, Stadmeyer, & Bouxsein, 2007). Femurs and vertebrae were placed in 70% ethanol for scanning, which was conducted at an energy level of 55 peak kV, intensity of 145 μA and integration time of 200 ms. Evaluation of skeletal microarchitecture was started ~1.0 mm from the cranial side of the L3 vertebral body, or 1.0 mm proximal from the condyles of the distal femur. A total of 160 consecutive 6 μm thick slices were acquired at an isotropic voxel dimension of 261μm3 and selected for analysis. Contours were drawn manually every 10 slices a few voxels away from the endocortical boundary to define the region of analysis. The remaining slice contours were iterated automatically. Cancellous bone was assessed for bone volume fractions (bone volume/total volume, BVTV), trabecular separation (Tb.Sp), number (Tb.N) and thickness (Tb.Th), connectivity density (Conn.D), structure model index (SMI) and material density using a Gaussian filter (σ = 0.8) (Bouxsein et al., 2010; Glatt et al., 2007). For femoral bone, user-defined thresholds were used and vertebral L3 were analyzed using 290 pernil equivalent to 465 mg hydroxyapatite/cm3 thresholds. Cortical bone was analyzed in femurs, where contours were iterated across 100 slices along the cortical shell of the femoral mid-shaft, excluding the marrow cavity. Analyses of BV/TV, cortical thickness, periosteal perimeter, endosteal perimeter, total cross-sectional and cortical bone area were performed using a Gaussian filter (σ = 0.8) and user-defined thresholds. The terminology and units used are in accordance with guidelines published in the Journal of Bone and Mineral Research (Bouxsein et al., 2010).
Bone Histomorphometry
Bone histomorphometric analysis was performed in 4 month old mice previously injected with calcein 20 mg/kg and demeclocycline 50 mg/kg at a 7 day interval and sacrificed 2 days after demeclocycline administration, as previously reported (Canalis, Schilling, Yee, Lee, & Zanotti, 2016; Canalis, Yu, Schilling, Yee, & Zanotti, 2018). L3 vertebrae were placed in 70% ethanol for fixation prior to being embedded in methyl methacrylate. Vertebral bodies were sectioned at a thickness of 5 μm along the coronal plane on a Microm microtome (Richards-Allan Scientific, Kalamazoo, MI). Static and dynamic parameters of bone morphometry were measured in a defined area at a magnification of 100x using OsteoMeasure software (Osteometrics, Atlanta, GA). Trabecular bone area, number and thickness, osteoblast, osteocyte and osteoclast number, osteoid and eroded surface were measured in toluidine blue (0.1%) stained sections. Mineralizing surface per bone surface and mineral apposition rate were measured on unstained sections visualized under UV light and values used to calculate bone formation rate. Terminology and units used for bone histomorphometry are those recommended by the Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral Research (Dempster et al., 2013; Parfitt et al., 1987).
Bone Marrow Stromal Cell Cultures
Bone marrow stromal cells were obtained from femurs and tibiae dissected from 6 to 8 week old Nfatc1loxP/loxP;Nfatc2loxP/loxP mice. Bone marrow cells were isolated by centrifugation following the removal of the epiphyseal ends and recovered in α-minimum essential medium (α-MEM, Life Technologies, Grand Island, NY). Cells were seeded at a density of 1.25 × 106 cells/cm2 in α-MEM supplemented with 15% heat-inactivated fetal bovine serum (FBS) and grown in an incubator in an atmosphere of 5% CO2 at 37°C. Cells in suspension were removed by replacing the culture medium 48 h after seeding and adherent cells were considered bone marrow stromal cells (Bianco & Gehron, 2000). Four to 5 days later adherent cells were digested with trypsin, replated and exposed to α-MEM containing 10% FBS, and grown to ~70% confluence, transferred to α-MEM supplemented with 2% FBS for 1 h and exposed overnight to 100 multiplicity of infection of replication defective recombinant adenoviruses. Adenoviral vector systems expressing Cre, to excise loxP flanked sequences (Ad-CMV-Cre), or green fluorescent protein (control, Ad-CMV-GFP, Vector Biolabs) both under the control of the cytomegalovirus (CMV) promoter were used. Cells were allowed to recover for 24 to 48 h and cultured in α-MEM 10% FBS to confluence and then in α-MEM supplemented with 10% FBS, 100 μg/ml ascorbic acid and 5 mM β-glycerophophate (all from Sigma-Aldrich) (Zanotti, Kalajzic, Aguila, & Canalis, 2014; Zanotti et al., 2011, 2013). Cell extracts were obtained for RNA determinations or cultures were stained with alizarin red to assess mineralization.
Quantitative Reverse Transcription-PCR (qRT-PCR)
Total RNA was extracted from cells with the RNeasy kit (Qiagen, Valencia, CA) in accordance with manufacturer’s instructions (Canalis et al., 2016; Canalis et al., 2018; Nazarenko, Lowe, et al., 2002; Nazarenko, Pires, Lowe, Obaidy, & Rashtchian, 2002). Equal amounts of RNA were reverse-transcribed using the iScript RT-PCR kit (BioRad, Carlsbad, CA) and amplified in the presence of specific primers (all primers from Integrated DNA Technologies, Coralville, IA; Table 1) with the iQSYBR Green Supermix or SsoAdvanced™ Universal SYBR Green Supermix (BioRad) at 60°C for 40 cycles. Copy number was determined by comparison with a serial dilution of cDNA for Nfatc1 (Addgene plasmid 11793), Nfatc2 (Addgene plasmid 11791) (both from A. Rao, La Jolla, CA), Bglap (J. Lian, Burlington, VT), Alpl and Rpl38 (American Type Culture Collection, ATCC, Manassas, VA). Amplification reactions were conducted in CFX96 qRT-PCR detection systems (BioRad), and fluorescence was monitored during every PCR cycle at the annealing step. Data are expressed as copy number corrected for Rpl38 expression (Kouadjo, Nishida, Cadrin-Girard, Yoshioka, & St-Amand, 2007).
Statistics
Data are reported as means ± S.D. Statistical differences were determined by unpaired Student’s t-test or 2-way analysis of variance with Holm-Šidák post-hoc analysis for pairwise or multiple comparisons.
RESULTS
General Characteristics of Nfatc1 and Nfatc2 Single and Dual Inactivation in Mature Osteoblasts
To study the consequences of the inactivation of Nfatc1 and Nfatc2 in the osteoblast lineage, the Nfatc1loxP, Nfatc2 loxP or both alleles were introduced into BGLAP-Cre heterozygous mice. Subsequently, BGLAP-Cre;Nfatc1loxP/loxP, BGLAP-Cre;Nfatc2loxP/loxP or BGLAP-Cre;Nfatc1loxP/loxP;Nfatc2loxP/loxP mice were crossed with Nfatc1loxP/loxP, Nfatc2loxP/loxP or Nfatc1loxP/loxP;Nfatc2loxP/loxP mice, respectively, to obtain BGLAP-Cre;Nfatc1Δ/Δ, BGLAP-Cre;Nfatc2Δ/Δ and BGLAP-Cre;Nfatc1Δ/Δ;Nfatc2Δ/Δ test mice and respective NfatcloxP/loxP control littermates. BGLAP-Cre;Nfatc1Δ/Δ, Nfatc2Δ/Δ and Nfatc1Δ/Δ;Nfatc2 Δ/Δ mice had a healthy appearance and their weight was comparable to the weight of control mice (Figure 1). BGLAP-Cre-dependent recombination was demonstrated in genomic DNA extracted from tibiae of BGLAP-Cre;Nfatc1Δ/Δ, or calvariae of Nfatc2Δ/Δ and Nfatc1Δ/Δ;Nfatc2Δ/Δ mice.
Vertebral Microarchitecture and Histomorphometry of Nfatc1 and Nfatc2 Inactivated Mice
Vertebral microarchitecture of 3 month old BGLAP-Cre;Nfatc1Δ/Δ and 4 month old BGLAP-Cre;Nfatc2Δ/Δ male and female mice revealed a mild decrease in trabecular bone volume when compared to Nfatc1loxP/loxP or Nfatc2loxP/loxP sex-matched littermate controls (Table 2). To rule out the possibility of genetic compensation between Nfatc1 and Nfatc2, vertebral microarchitecture was examined in mice harboring the dual deletion of Nfatc1 and Nfatc2 in Bglap-expressing cells. Vertebral microarchitecture of 4 month old male (Figure 2) and female (Figure 3) BGLAP-Cre;Nfatc1Δ/Δ;Nfatc2Δ/Δ mice demonstrated a 21% and a 27% decrease in bone volume/total volume when compared to sex-matched littermate controls. This decrease was associated with a significant decrease in trabecular number and connectivity density whereas trabecular thickness was not affected. SMI was increased demonstrating a tendency toward rod-like weaker trabeculae. Female mice harboring BGLAP-Cre;Nfatc1Δ/Δ;Nfatc2Δ/Δ alleles also were osteopenic at 1 month of age (Figure 3) whereas mature male mice were osteopenic but at 1 month of age had L3 microarchitecture comparable to controls (Figure 2). Bone histomorphometry confirmed the osteopenic phenotype and demonstrated that BGLAP-Cre;Nfatc1Δ/Δ;Nfatc2Δ/Δ male mice had a significant decrease in osteoblast number and osteoblast and osteoid surface but neither osteoclast number nor eroded surface were affected revealing normal bone resorption (Table 3, Figure 4). Histomorphometric analysis of L3 from BGLAP-Cre;Nfatc1Δ/Δ;Nfatc2Δ/Δ 4 month old female mice revealed similar trends as male mice, but histomorphometric parameters were not significantly different from controls (p > 0.05; not shown).
Table 2.
Nfatc1 | Males | Females | ||
---|---|---|---|---|
Control n = 8 |
Nfatc1Δ/Δ n = 8 |
Control n = 9 |
Nfatc1Δ/Δ n = 6 |
|
Distal Femur Trabecular Bone | ||||
Bone Volume/Total Volume (%) | 12.6 ± 0.9 | 10.8 ± 1.4* | 13.0 ± 2.0 | 10.9 ± 1.0* |
Trabecular Separation (μm) | 185 ± 9 | 187 ± 10 | 220 ± 10 | 239 ± 14* |
Trabecular Number (1/mm) | 5.2 ± 0.3 | 5.2 ± 0.3 | 4.5 ± 0.2 | 4.1 ± 0.2* |
Trabecular Thickness (μm) | 28 ± 1 | 26 ± 1* | 31 ± 3 | 31 ± 1 |
Connectivity Density (1/mm3) | 418 ± 48 | 422 ± 52 | 380 ± 72 | 306 ± 63 |
Structure Model Index | 1.2 ± 0.1 | 1.4 ± 0.1* | 1.2 ± 0.3 | 1.3 ± 0.1 |
Density of Material (mg HA/cm3) | 947 ± 11 | 960 ± 21 | 928 ± 33 | 938 ± 10 |
Nfatc2 | Males | Females | ||
---|---|---|---|---|
Control n = 8 |
Nfatc2Δ/Δ n = 9 |
Control n = 8 |
Nfatc2Δ/Δ n = 8 |
|
Distal Femur Trabecular Bone | ||||
Bone Volume/Total Volume (%) | 11.3 ± 0.8 | 10.2 ± 1.3+ | 8.3 ± 0.7 | 6.9 ± 1.2* |
Trabecular Separation (μm) | 201 ± 9 | 199 ± 13 | 255 ± 16 | 257 ± 15 |
Trabecular Number (1/mm) | 5.0 ± 0.2 | 5.0 ± 0.3 | 4.0 ± 0.3 | 3.9 ± 0.2 |
Trabecular Thickness (μm) | 29 ± 1 | 28 ± 2 | 31 ± 2 | 28 ± 1* |
Connectivity Density (1/mm3) | 350 ± 44 | 342 ± 86 | 237 ± 44 | 252 ± 70 |
Structure Model Index | 1.3 ± 0.2 | 1.5 ± 0.2 | 1.7 ± 0.1 | 1.9 ± 0.2* |
Density of Material (mg HA/cm3) | 1012 ± 18 | 1009 ± 22 | 973 ± 24 | 977 ± 29 |
μCT was performed in L3 vertebral bodies from 3 month old male and female BGLAP-Cre;Nfatc1Δ/Δ mice and 4 month old BGLAP-Cre;Nfatc2Δ/Δ mice and sex-matched Nfatc1loxP/loxP or Nfatc2loxP/loxP littermates. Values are means ± SD.
Significantly different between control and BGLAP-Cre;Nfatc1Δ/Δ or control and BGLAP-Cre;Nfatc2Δ/Δ, p < 0.05 by unpaired t-test;
p = 0.058.
Table 3.
Control n = 4 |
Nfatc1Δ/Δ;2Δ/Δ N = 9 |
|
---|---|---|
Bone Volume/Total Volume (%) | 22.1 ± 5.4 | 16.4 ± 4.0+ |
Trabecular Number (1/mm) | 4.5 ± 0.7 | 3.9 ± 0.8 |
Trabecular Thickness (μm) | 49 ± 6 | 43 ± 7 |
Osteoblasts/Bone Perimeter (1/mm) | 6.1 ± 0.9 | 3.4 ± 1.4* |
Osteoblast Surface/Bone Surface (%) | 7.7 ± 1.6 | 4.3 ± 2.0* |
Osteoid Surface/Bone Surface (%) | 0.8 ± 0.3 | 0.1 ± 0.1* |
Osteoclasts/Bone Perimeter (1/mm) | 1.6 ± 0.4 | 2.1 ± 0.8 |
Eroded Surface/Bone Surface (%) | 1.8 ± 0.7 | 2.1 ± 1.0 |
Mineral Apposition Rate (μm/day) | 0.8 ± 0.2 | 0.8 ± 0.1 |
Mineralizing Surface/Bone Surface (%) | 2.6 ± 0.7 | 1.7 ± 1.0 |
Bone Formation Rate (μm3/μm2/day) | 0.022 ± 0.01 | 0.014 ± 0.01 |
Bone histomorphometry was performed in L3 vertebral bodies from 4 month old male BGLAP-Cre;Nfatc1Δ/Δ;Nfatc2Δ/Δ mice and sex-matched Nfatc1loxP/loxP;Nfatc2loxP/loxP littermates (control). Values are means ± SD.
Significantly different between BGLAP-Cre;Nfatc1Δ/Δ;Nfatc2Δ/Δ and control, p < 0.05;
p 0.0547.
Femoral Microarchitecture of Nfatc1 and Nfatc2 Inactivated Mice
In contrast to the osteopenic vertebral phenotype of Nfatc1 and Nfatc2 null mice, femoral architecture of 1, 3 and 6 month old male and female BGLAP-Cre;Nfatc1Δ/Δ mice revealed no phenotypic differences compared to Nfatc1loxP/loxP sex-matched littermate controls (Table 4). Similarly, femoral microarchitecture of 1 and 4 month old male and female BGLAP-Cre;Nfatc2Δ/Δ revealed no differences in either cancellous or cortical bone when compared to Nfatc2loxP/loxP sex-matched littermate controls (Table 5). In addition, the femoral microarchitecture of the dual Nfatc1;Nfatc2 deletion in Bglap-expressing cells demonstrated no appreciably differences in either trabecular or cortical bone between male and female 1 and 4 month old BGLAP-Cre;Nfatc1Δ/Δ;Nfatc2Δ/Δ and sex-matched Nfatc1loxP/loxP;Nfatc2loxP/loxP littermate controls (Table 6).
Table 4.
Males | 1 Month | 3 Month | 6 Month | |||
---|---|---|---|---|---|---|
Control n = 4 |
Nfatc1Δ/Δ n = 4 |
Control n = 5 |
Nfatc1Δ/Δ n = 5 |
Control n = 6 |
Nfatc1Δ/Δ n = 6 |
|
Distal Femur Trabecular Bone | ||||||
Bone Volume/Total Volume (%) | 5.9 ± 1.2 | 5.7 ± 2.1 | 3.1 ± 1.0 | 2.9 ± 0.4 | 2.1 ± 0.2 | 2.0 ± 0.6 |
Trabecular Separation (μm) | 183 ± 15 | 180 ± 25 | 232 ± 10 | 226 ± 7 | 270 ± 14 | 272 ± 23 |
Trabecular Number (1/mm) | 5.5 ± 0.5 | 5.7 ± 0.9 | 4.3 ± 0.2 | 4.4 ± 0.1 | 3.7 ± 0.2 | 3.7 ± 0.3 |
Trabecular Thickness (μm) | 21 ± 1 | 20 ± 1 | 25 ± 2 | 23 ± 2 | 27 ± 2 | 25 ± 2 |
Connectivity Density (1/mm3) | 277 ± 130 | 324 ± 268 | 46 ± 28 | 29 ± 22 | 23 ± 15 | 26 ± 24 |
Structure Model Index | 3.2 ± 0.1 | 3.2 ± 0.2 | 3.2 ± 0.2 | 3.1 ± 0.1 | 3.4 ± 0.1 | 3.4 ± 0.3 |
Density of Material (mg HA/cm3) | 895 ± 7 | 895 ± 18 | 987 ± 10 | 977 ± 31 | 1025 ± 18 | 1040 ± 12 |
n = 4 | n = 4 | n = 4 | n = 5 | n = 5 | n = 6 | |
Femoral Midshaft Cortical Bone | ||||||
Bone Volume/Total Volume (%) | 82.9 ± 1.8 | 81.5 ± 1.3 | 87.5 ± 0.5 | 87.1 ± 0.8 | 89.3 ± 1.1 | 89.5 ± 0.5 |
Porosity (%) | 17.1 ± 1.8 | 18.5 ± 1.3 | 12.5 ± 0.5 | 12.9 ± 0.8 | 10.7 ± 1.1 | 10.5 ± 0.5 |
Cortical Thickness (μm) | 88 ± 10 | 80 ± 5 | 152 ± 6 | 146 ± 9 | 156 ± 11 | 153 ± 4 |
Total Area (mm2) | 1.4 ± 0.1 | 1.4 ± 0.1 | 1.7 ± 0.1 | 1.7 ± 0.1 | 1.8 ± 0.1 | 1.7 ± 0.1 |
Bone Area (mm2) | 0.5 ± 0.1 | 0.4 ± 0.1 | 0.8 ± 0.1 | 0.7 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 |
Periosteal Perimeter (mm) | 4.2 ± 0.1 | 4.3 ± 0.2 | 4.6 ± 0.1 | 4.6 ± 0.1 | 4.7 ± 0.2 | 4.6 ± 0.2 |
Endocortical Perimeter (mm) | 3.5 ± 0.1 | 3.5 ± 0.2 | 3.3 ± 0.1 | 3.4 ± 0.1 | 3.5 ± 0.2 | 3.5 ± 0.2 |
Density of Material (mg HA/cm3) | 1025 ± 5.4 | 1014 ± 17.6 | 1208 ± 8 | 1214 ± 21 | 1199 ± 16 | 1192 ± 22 |
Females | 1 Month | 3 Month | 6 Month | |||
---|---|---|---|---|---|---|
Control n = 6 |
Nfatc1Δ/Δ n = 3 |
Control n = 5 |
Nfatc1Δ/Δ n = 4 |
Control n = 6 |
Nfatc1Δ/Δ n = 6 |
|
Distal Femur Trabecular Bone | ||||||
Bone Volume/Total Volume (%) | 6.3 ± 1.4 | 5.5 ± 2.3 | 1.5 ± 0.4 | 1.4 ± 0.6 | 0.9 ± 0.4 | 0.8 ± 0.2 |
Trabecular Separation (μm) | 176 ± 18 | 193 ± 53 | 335 ± 20 | 345 ± 15 | 444 ± 57 | 465 ± 52 |
Trabecular Number (1/mm) | 5.7 ± 0.5 | 5.5 ± 1.4 | 3.0 ± 0.2 | 2.9 ± 0.1 | 2.3 ± 0.3 | 2.2 ± 0.2 |
Trabecular Thickness (μm) | 21 ± 1 | 20 ± 1 | 30 ± 4 | 29 ± 4 | 32 ± 6 | 34 ± 5 |
Connectivity Density (1/mm3) | 367 ± 111 | 243 ± 250 | 12 ± 8 | 19 ± 15 | 13 ± 12 | 10 ± 5 |
Structure Model Index | 3.1 ± 0.2 | 3.2 ± 0.2 | 3.7 ± 0.2 | 3.6 ± 0.3 | 3.7 ± 0.6 | 3.6 ± 0.1 |
Density of Material (mg HA/cm3) | 892 ± 14 | 899 ± 19 | 995 ± 15 | 996 ± 20 | 1039 ± 29 | 1050 ± 125 |
n = 5 | n = 3 | n = 5 | n = 3 | n = 5 | n = 6 | |
Bone Volume/Total Volume (%) | 81.9 ± 1.6 | 82.2 ± 2.0 | 87.9 ± 0.7 | 87.2 ± 0.9 | 90.0 ± 0.8 | 90.2 ± 0.8 |
Porosity (%) | 18.1 ± 1.6 | 17.8 ± 2.0 | 12.1 ± 0.7 | 128 ± 0.9 | 10.0 ± 0.8 | 9.8 ± 0.8 |
Cortical Thickness (μm) | 82 ± 9 | 85 ± 11 | 156 ± 9 | 147 ± 10 | 180 ± 4 | 175 ± 5 |
Total Area (mm2) | 1.4 ± 0.2 | 1.4 ± 0.1 | 1.7 ± 0.1 | 1.7 ± 0.1 | 1.6 ± 0.1 | 1.7 ± 0.1 |
Bone Area (mm2) | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.8 ± 0.11 | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 |
Periosteal Perimeter (mm) | 4.2 ± 0.3 | 4.1 ± 0.2 | 4.6 ± 0.1 | 4.6 ± 0.1 | 4.5 ± 0.2 | 4.6 ± 0.1 |
Endocortical Perimeter (mm) | 3.5 ± 0.2 | 3.4 ± 0.1 | 3.3 ± 0.1 | 3.4 ± 0.1 | 3.2 ± 0.1 | 3.3 ± 0.1 |
Density of Material (mg HA/cm3) | 1007 ± 16 | 1022 ± 14 | 1217 ± 14 | 1221 ± 23 | 1225 ± 14 | 1219 ± 21 |
μCT was performed in distal femurs for trabecular bone and midshaft for cortical bone from 1, 3 and 6 month old male and female BGLAP-Cre;Nfatc1Δ/Δ mice and sex-matched control littermates. Values are means ± SD.
Table 5.
Males | 1 Month | 4 Month | ||
---|---|---|---|---|
Control n = 6 |
Nfatc2Δ/Δ n = 5 |
Control n = 7 |
Nfatc2Δ/Δ n = 6 |
|
Distal Femur Trabecular Bone | ||||
Bone Volume/Total Volume (%) | 4.3 ± 0.9 | 4.5 ± 0.8 | 10.1 ± 3.4 | 9.4 ± 4.3 |
Trabecular Separation (μm) | 239 ± 25 | 234 ± 17 | 223 ± 15 | 226 ± 12 |
Trabecular Number (1/mm) | 4.2 ± 0.4 | 4.3 ± 0.3 | 4.5 ± 0.3 | 4.4 ± 0.2 |
Trabecular Thickness (μm) | 24 ± 1 | 23 ± 1 | 40 ± 3 | 38 ± 7 |
Connectivity Density (1/mm3) | 170 ± 86 | 174 ± 97 | 198 ± 57 | 198 ± 47 |
Structure Model Index | 3.1 ± 0.2 | 3.1 ± 0.2 | 2.2 ± 0.5 | 2.3 ± 0.5 |
Density of Material (mg HA/cm3) | 811 ± 5 | 806 ± 11 | 959 ± 26 | 971 ± 28 |
Femoral Midshaft Cortical Bone | ||||
Bone Volume/Total Volume (%) | 81.6 ± 0.8 | 81.4 ± 1.0 | 89.2 ± 0.8 | 89.5 ± 0.2 |
Porosity (%) | 18.4 ± 0.8 | 18.6 ± 1.0 | 10.8 ± 0.8 | 10.5 ± 0.2 |
Cortical Thickness (μm) | 85 ± 4 | 87 ± 4 | 167 ± 1 | 168 ± 6 |
Total Area (mm2) | 1.4 ± 0.1 | 1.6 ± 0.1 | 1.9 ± 0.2 | 1.9 ± 0.1 |
Bone Area (mm2) | 0.4 ± 0.1 | 0.5 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.1 |
Periosteal Perimeter (mm) | 4.2 ± 0.2 | 4.4 ± 0.2 | 4.9 ± 0.3 | 4.8 ± 0.2 |
Endocortical Perimeter (mm) | 3.5 ± 0.2 | 3.7 ± 0.1 | 3.6 ± 0.3 | 3.5 ± 0.2 |
Density of Material (mg HA/cm3) | 811 ± 5 | 806 ± 11 | 1218 ± 20 | 1217 ± 14 |
Females | 1 Month | 4 Month | ||
---|---|---|---|---|
Control n = 6 |
Nfatc2Δ/Δ n = 6 |
Control n = 7 |
Nfatc2Δ/Δ n = 7 |
|
Distal Femur Trabecular Bone | ||||
Bone Volume/Total Volume (%) | 3.8 ± 0.7 | 3.8 ± 0.6 | 4.7 ± 1.0 | 5.5 ± 0.8 |
Trabecular Separation (μm) | 254 ± 53 | 250 ± 25 | 305 ± 11 | 296 ± 29 |
Trabecular Number (1/mm) | 4.1 ± 0.7 | 4.1 ± 0.4 | 3.3 ± 0.1 | 3.4 ± 0.3 |
Trabecular Thickness (μm) | 23 ± 1 | 23 ± 1 | 39 ± 3 | 41 ± 2 |
Connectivity Density (1/mm3) | 149 ± 49 | 120 ± 32 | 108 ± 34 | 112 ± 31 |
Structure Model Index | 3.1 ± 0.1 | 3.1 ± 0.2 | 3.0 ± 0.3 | 2.7 ± 0.2 |
Density of Material (mg HA/cm3) | 804 ± 5 | 807 ± 3 | 1017 ± 28 | 997 ± 41 |
Femoral Midshaft Cortical Bone | ||||
Bone Volume/Total Volume (%) | 80.4 ± 2.3 | 82.6 ± 0.9 | 89.4 ± 0.6 | 89.0 ± 1.5 |
Porosity (%) | 19.6 ± 2.3 | 17.4 ± 0.9 | 10.6 ± 0.6 | 11.0 ± 1.5 |
Cortical Thickness (μm) | 81 ± 7 | 90 ± 0.3* | 174 ± 4 | 178 ± 11 |
Total Area (mm2) | 1.4 ± 0.2 | 1.4 ± 0.2 | 1.6 ± 0.1 | 1.6 ± 0.1 |
Bone Area (mm2) | 0.4 ± 0.1 | 0.5 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 |
Periosteal Perimeter (mm) | 4.1 ± 0.3 | 4.2 ± 0.3 | 4.5 ± 0.1 | 4.5 ± 0.1 |
Endocortical Perimeter (mm) | 3.4 ± 0.2 | 3.5 ± 0.3 | 3.2 ± 0.1 | 3.2 ± 0.2 |
Density of Material (mg HA/cm3) | 985 ± 19 | 998 ± 7 | 1250 ± 30 | 1254 ± 24 |
μCT was performed in distal femurs for trabecular bone and midshaft for cortical bone from 1 and 4 month old male and female BGLAP-Cre;Nfatc2Δ/Δ mice and sex-matched control littermates. Values are means ± SD.
Significantly different between control and BGLAP-Cre;Nfatc2Δ/Δ, p < 0.05 by unpaired t-test.
Table 6.
Males | 1 Month | 4 Month | ||
---|---|---|---|---|
Control n = 6 |
Nfatc1Δ/Δ;c2Δ/Δ n = 6 |
Control n = 3 |
Nfatc1Δ/Δ;c2Δ/Δ n = 8 |
|
Distal Femur Trabecular Bone | ||||
Bone Volume/Total Volume (%) | 7.4 ± 3.9 | 7.0 ± 3.2 | 10.4 ± 4.0 | 7.5 ± 1.5 |
Trabecular Separation (μm) | 216 ± 22 | 221 ± 15 | 217 ± 17 | 235 ± 14 |
Trabecular Number (1/mm) | 4.7 ± 0.4 | 4.6 ± 0.3 | 4.6 ± 0.3 | 4.2 ± 0.2 |
Trabecular Thickness (μm) | 20 ± 1 | 20 ± 3 | 38 ± 5 | 36 ± 3 |
Connectivity Density (1/mm3) | 166 ± 89 | 129 ± 88 | 211 ± 67 | 149 ± 36 |
Structure Model Index | 3.2 ± 0.3 | 3.3 ± 0.2 | 2.0 ± 0.6 | 2.4 ± 0.3 |
Density of Material (mg HA/cm3) | 892 ± 41 | 903 ± 41 | 938 ± 8 | 943 ± 10 |
Femoral Midshaft Cortical Bone | ||||
Bone Volume/Total Volume (%) | 83.5 ± 1.5 | 84.6 ± 1.2 | 89.8 ± 0.3 | 89.4 ± 0.5 |
Porosity (%) | 16.5 ± 1.5 | 15.4 ± 1.2 | 10.2 ± 0.3 | 10.6 ± 0.5 |
Cortical Thickness (μm) | 77 ± 7 | 78 ± 5 | 174 ± 4 | 166 ± 7 |
Total Area (mm2) | 1.3 ± 0.1 | 1.3 ± 0.2 | 1.7 ± 0.1 | 1.9 ± 0.3 |
Bone Area (mm2) | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.8 ± 0.1 | 0.9 ± 0.1 |
Periosteal Perimeter (mm) | 4.0 ± 0.2 | 4.1 ± 0.3 | 4.6 ± 0.2 | 4.9 ± 0.3 |
Endocortical Perimeter (mm) | 3.4 ± 0.2 | 3.5 ± 0.2 | 3.3 ± 0.2 | 3.6 ± 0.3 |
Density of Material (mg HA/cm3) | 926 ± 22 | 951 ± 25 | 1251 ± 14 | 1235 ± 16 |
Females | 1 Month | 4 Month | ||
---|---|---|---|---|
Control n = 5 |
Nfatc1Δ/Δ;c2Δ/Δ n = 6 |
Control n = 6 |
Nfatc1Δ/Δ;c2Δ/Δ n = 6 |
|
Distal Femur Trabecular Bone | ||||
Bone Volume/Total Volume (%) | 4.1 ± 1.8 | 3.8 ± 0.9 | 4.4 ± 1.2 | 3.6 ± 0.2 |
Trabecular Separation (μm) | 203 ± 26 | 223 ± 35 | 294 ± 23 | 320 ± 32 |
Trabecular Number (1/mm) | 5.0 ± 0.7 | 4.6 ± 0.7 | 3.4 ± 0.2 | 3.2 ± 0.1 |
Trabecular Thickness (μm) | 19 ± 2 | 20 ± 1 | 34 ± 3 | 37 ± 3 |
Connectivity Density (1/mm3) | 193 ± 161 | 168 ± 59 | 87 ± 27 | 46 ± 11* |
Structure Model Index | 3.2 ± 0.2 | 3.2 ± 0.2 | 2.8 ± 0.2 | 3.0 ± 0.2* |
Density of Material (mg HA/cm3) | 883 ± 15 | 884 ± 8 | 920 ± 28 | 952 ± 19* |
Femoral Midshaft Cortical Bone | ||||
Bone Volume/Total Volume (%) | 82.8 ± 3.9 | 84.6 ± 0.9 | 90.0 ± 0.2 | 89.9 ± 0.3 |
Porosity (%) | 17.2 ± 3.9 | 15.4 ± 0.9 | 10.0 ± 0.2 | 10.1 ± 0.3 |
Cortical Thickness (μm) | 74 ± 12 | 78 ± 3 | 175 ± 5 | 173 ± 6 |
Total Area (mm2) | 1.3 ± 0.2 | 1.4 ± 0.2 | 1.5 ± 0.1 | 1.6 ± 0.1 |
Bone Area (mm2) | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 |
Periosteal Perimeter (mm) | 4.1 ± 0.3 | 4.2 ± 0.3 | 4.4 ± 0.1 | 4.5 ± 0.1 |
Endocortical Perimeter (mm) | 3.5 ± 0.3 | 3.6 ± 0.3 | 3.1 ± 0.1 | 3.2 ± 0.1 |
Density of Material (mg HA/cm3) | 941 ± 37 | 948 ± 22 | 1269 ± 7 | 1268 ± 13 |
μCT was performed in distal femurs for trabecular bone and midshaft for cortical bone from 1 and 4 month old male and female BGLAP-Cre;Nfatc1Δ/Δ;Nfatc2Δ/Δ mutant mice and sex-matched control littermates. Values are means ± SD.
Significantly different between control and BGLAP-Cre;Nfatc1Δ/Δ;Nfatc2Δ/Δ, p < 0.05 by unpaired t-test.
Bone Marrow Stromal Cell Cultures from Nfatc1 and Nfatc2 Inactivated Mice
To determine whether Nfatc1 or Nfatc2 had a direct effect in cells of the osteoblast lineage, osteoblastogenesis was studied in bone marrow stromal cells following the deletion of Nfatc1 and Nfatc2. Bone marrow stromal cells from Nfatc1loxP/loxP;Nfatc2loxP/loxP mice were transduced with Ad-CMV-Cre to delete Nfatc1 and Nfatc2 and compared to control cultures transduced with Ad-CMV-GFP. The downregulation of Nfatc1 and Nfatc2 resulted in a transient increase in Alpl and Bglap mice at confluence and a more sustained decrease in Alpl and Bglap mRNA expression as well as a modest decrease in mineralization, as the culture progressed (Figure 5). This confirms that NFATc1 and NFATc2 are required for optimal osteoblast differentiation in vitro.
DISCUSSION
In the present work, we explored the direct effects of NFATc1 and NFATc2 on osteoblast function following the inactivation of Nfatc1 and Nfatc2, singly and in combination, in cells of the osteoblast lineage. The inactivation of either Nfatc1, Nfatc2 or Nfatc1 and Nfatc2 in Bglap expressing mature osteoblasts resulted in vertebral osteopenia in mature mice. The osteopenia was observed in mature male and female mice, and was modestly more pronounced in the context of the dual Nfatc1 and Nfatc2 deletion. This is to be expected and indicative of possible genetic compensation between the 2 transcription factors. These results would indicate that NFATc1 and NFATc2 are necessary for optimal skeletal homeostasis in cancellous vertebral bone. In contrast to the vertebral osteopenia, femoral bone was not affected by the inactivation of Nfatc1 and Nfatc2 singly or in combination. There is not an obvious explanation for the predilection of vertebral sites as a consequence of the Nfatc1, Nfatc2 inactivation. This could possibly be due to the fact that vertebral bodies are mostly constituted by cancellous bone, or is possibly related to different levels of expression of Nfatc1 and Nfatc2 in vertebral and femoral bone or in the expression of Cre leading to greater recombination and downregulation of target genes in vertebral bones.
Our findings are in contrast to previous work demonstrating that the downregulation of calcineurin in Bglap-expressing cells results in an increase in bone volume and bone formation (Yeo et al., 2007). Although calcineurin is required for NFATc activation, it is possible that the phenotype observed following the osteoblast-specific deletion of Cnb1, encoding for calcineurin, is due to actions unrelated to NFATc1 and NFATc2 activation. It is worthy to note that the global inactivation of calcineurin Aα results in osteopenia due to suppressed bone formation, a phenotype that is opposite to the one reported for the conditional deletion of Cnb1 in osteoblasts and more in line with the present work (Sun et al., 2005). The disparity in the results obtained between the two models of calcineurin inactivation may be related to differences in mouse models and in phenotypes achieved following either the global or the cell-specific deletion of the gene in question.
The deletion of Nfatc1and Nfatc2 in cells of the osteoblast lineage resulted in a decrease in osteoblast gene markers in vitro, and these results are in accordance with the osteopenic phenotype observed at vertebral sites in vivo, and the decreased number of osteoblasts observed in mature male BGLAP-Cre;Nfatc1Δ/Δ;Nfatc2Δ/Δ mice. The results would suggest that the osteopenia is secondary to decreased osteoblast function/differentiation. Although the number of osteoblasts as well as osteoid surface were decreased in BGLAP-Cre;Nfatc1Δ/Δ;Nfatc2Δ/Δ mice, mineralizing surface and bone formation were modestly (35%) and not significantly reduced. This is possible due to a modest and somewhat variable affect but may also reflect that NFATc1 and NFATc2 play a limited role in the regulation of bone formation. Our findings are different than those obtained following the downregulation of calcineurin in cells of the osteoblast lineage (Yeo et al., 2007). The deletion of Cnb1 in osteoblasts resulted in an increase in Bglap, Col1a1 and Alpl mRNA levels suggesting that Cnb1 suppresses osteoblast function (Yeo et al., 2007). Contrary to these results, we find that NFATc1 in combination with NFATc2 are necessary for optimal osteoblast function, since their inactivation results in a decrease in Alpl and Bglap expression. An explanation for the discrepant results is that the phenotype obtained by the downregulation of Cnb1 may be due to an alteration in the expression or function of calcineurin-dependent genes other than Nfatc1or Nfatc2.
Our results are more in line with work in Nfatc1 and Cnb1 null mice demonstrating a stimulatory role of NFATc1 in bone formation. However, these studies analyzed the phenotype of global Nfatc1 null mice, and the effects in osteoblasts could have been modified by changes in function and behavior of a variety of skeletal and non-skeletal cells affected by the NFATc1 deficiency leading to osteopenia in Nfatc1 and Cnb1 null mice (Sun et al., 2005; Winslow et al., 2006). The decrease in osteoblast gene expression observed in Nfatc1;Nfatc2 deficient osteoblasts is in line with previous work showing that NFATs cooperate with osterix to regulate bone formation in osteoblasts (Koga et al., 2005).
The inactivation of Nfatc1 and Nfatc2 in osteoblasts results in a vertebral skeletal phenotype characterized by osteopenia demonstrating that NFATc1 and NFATc2 are necessary for optimal skeletal homeostasis. However, delivery of caNFATc2 to Col1a1-expressing osteoblastic cells causes femoral bone osteopenia secondary to decreased bone formation (Zanotti & Canalis, 2015). This inhibitory role of NFATc2 might be attributed to the forced overexpression of the constitutively active form of the transcriptional regulator. It is possible that under basal conditions, NFATc2 has a role in the maintenance of osteoblast function but its overexpression at supraphysiological levels results in an inhibitory effect.
NFATc1 and NFATc2 are physiologically relevant to chondrogenesis. NFATc1 and NFATc2 are repressors of chondrogenesis and cartilage growth. Deletion of Nfatc2 leads to the ectopic formation of cartilage surrounding synovial tissue and to the development of osteoarthritis particularly when associated with the deletion of Nfatc1 (Greenblatt et al., 2013; Ranger et al., 1998; Rodova et al., 2011). Most of the manifestations of the disruption of Nfatc2 appear in postnatal and adult life since Nfatc2 is not expressed during the early developmental stages of cartilage formation (Ranger et al., 1998). NFATc1 and NFATc2 play a restrictive role in osteochondral growth, and as a consequence their inactivation leads to entheseal osteochondromas (Ge et al., 2016).
The observations may suggest a more important function of NFATc1 and NFATc2 in chondrocytes than in mature osteoblasts (Zanotti et al., 2011, 2013). However, our results do not exclude a more pronounced effect of NFATc1 and NFATc2 early in the osteoblastogenesis program since the BGLAP promoter used to direct Cre-dependent deletion of Nfatc1 and Nfatc2 is expressed in mature osteoblasts (Matthews et al., 2016).
Recently, we reported that a mouse model of Hajdu Cheney Syndrome associated with a NOTCH2 gain-of-function is sensitized to the development of osteoarthritis (Zanotti, Yu, Bridgewater, Wolf, & Canalis, 2018). Notch signaling represses Nfatc1, but induces Nfatc2 by post-transcriptional mechanisms and it is possible that the NFATc2 induction acts as a mechanism to protect joint integrity (Greenblatt et al., 2013; Zanotti & Canalis, 2013; Zanotti et al., 2011, 2013). NFATc1 and NFATc2 interact with Notch signaling in osteoblasts and compete with the Notch transcriptional complex for binding to DNA with a consequent downregulation of Notch signaling (Zanotti et al., 2013). The inactivation of Nfatc1 and Nfatc2 in bone marrow stromal cells resulted in a downregulation of Hey1 expression without a decrease in Hey2, HeyL and Hes1 expression (data not shown). This would suggest that the decrease in Hey1 mRNA is independent of a generalized downregulation of Notch signaling, and that Notch signaling is not significantly affected under conditions of Nfatc inactivation as it is under conditions of NFATc overexpression.
CONCLUSIONS
In conclusion, the present work demonstrates that NFATc1 and NFATc2 are necessary for optimal osteoblast differentiation and function and the maintenance of skeletal homeostasis at vertebral but not femoral sites.
ACKNOWLEDGMENTS
The authors thank J. Lian for Bglap cDNA, A. Rao for Nfatc1 and Nfatc2 cDNA, and Sarah Bosco and Mary Yurczak for assistance.
This work was supported by grant AR068160 (EC) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Footnotes
Disclosures: The authors declare no conflicts of interest with the contents of this article. The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
- Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM, … Glimcher LH (2008). NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. The Journal of clinical investigation, 118(11), 3775–3789. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, … Takayanagi H (2005). Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. Journal of Experimental Medicine, 202(9), 1261–1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bauer W, Rauner M, Haase M, Kujawski S, Arabanian LS, Habermann I, … Kiani A (2011). Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking the transcription factor NFATc2. Haematologica, 96(11), 1580–1588. doi: 10.3324/haematol.2011.042515 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bianco P, & Gehron RP (2000). Marrow stromal stem cells. The Journal of clinical investigation, 105(12), 1663–1668. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, & Muller R (2010). Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. Journal of Bone and Mineral Research, 25(7), 1468–1486. [DOI] [PubMed] [Google Scholar]
- Canalis E, Schilling L, Yee SP, Lee SK, & Zanotti S (2016). Hajdu Cheney Mouse Mutants Exhibit Osteopenia, Increased Osteoclastogenesis and Bone Resorption. Journal of Biological Chemistry, 291, 1538–1551. doi: 10.1074/jbc.M115.685453 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Canalis E, Yu J, Schilling L, Yee SP, & Zanotti S (2018). The lateral meningocele syndrome mutation causes marked osteopenia in mice. Journal of Biological Chemistry, 293(36), 14165–14177. doi: 10.1074/jbc.RA118.004242 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chow W, Hou G, & Bendeck MP (2008). Glycogen synthase kinase 3beta regulation of nuclear factor of activated T-cells isoform c1 in the vascular smooth muscle cell response to injury. Experimental Cell Research, 314(16), 2919–2929. [DOI] [PubMed] [Google Scholar]
- Crabtree GR, & Olson EN (2002). NFAT signaling: choreographing the social lives of cells. Cell, 109 Suppl, S67–S79. [DOI] [PubMed] [Google Scholar]
- Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, … Parfitt AM (2013). Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. Journal of Bone and Mineral Research, 28(1), 2–17. doi: 10.1002/jbmr.1805 [doi] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ge X, Tsang K, He L, Garcia RA, Ermann J, Mizoguchi F, … Aliprantis AO (2016). NFAT restricts osteochondroma formation from entheseal progenitors. JCI Insight, 1(4), e86254. doi: 10.1172/jci.insight.86254 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Glatt V, Canalis E, Stadmeyer L, & Bouxsein ML (2007). Age-Related Changes in Trabecular Architecture Differ in Female and Male C57BL/6J Mice. Journal of Bone and Mineral Research, 22(8), 1197–1207. [DOI] [PubMed] [Google Scholar]
- Graef IA, Chen F, & Crabtree GR (2001). NFAT signaling in vertebrate development. Curr. Opin. Genet Dev, 11(5), 505–512. [DOI] [PubMed] [Google Scholar]
- Greenblatt MB, Ritter SY, Wright J, Tsang K, Hu D, Glimcher LH, & Aliprantis AO (2013). NFATc1 and NFATc2 repress spontaneous osteoarthritis1. Proceedings of the National Academy of Sciences of the United States of America, 110(49), 19914–19919. doi:1320036110 [pii]; 10.1073/pnas.1320036110 [doi] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hogan PG, Chen L, Nardone J, & Rao A (2003). Transcriptional regulation by calcium, calcineurin, and NFAT. Genes & Development, 17(18), 2205–2232. [DOI] [PubMed] [Google Scholar]
- Ikeda F, Nishimura R, Matsubara T, Hata K, Reddy SV, & Yoneda T (2006). Activation of NFAT signal in vivo leads to osteopenia associated with increased osteoclastogenesis and bone-resorbing activity. Journal of Immunology, 177(4), 2384–2390. [DOI] [PubMed] [Google Scholar]
- Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, … Yoneda T (2004). Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. Journal of Clinical Investigation, 114(4), 475–484. doi: 10.1172/JCI19657 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, … Takeya T (2002). Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. Journal of Biological Chemistry, 277(43), 41147–41156. doi: 10.1074/jbc.M205063200 [DOI] [PubMed] [Google Scholar]
- Koga T, Matsui Y, Asagiri M, Kodama T, d. C. B, Nakashima K, & Takayanagi H (2005). NFAT and Osterix cooperatively regulate bone formation. Nature Medicine, 11(8), 880–885. [DOI] [PubMed] [Google Scholar]
- Kouadjo KE, Nishida Y, Cadrin-Girard JF, Yoshioka M, & St-Amand J (2007). Housekeeping and tissue-specific genes in mouse tissues. BMC Genomics, 8, 127. doi: 10.1186/1471-2164-8-127 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, … Wagner EF (2004). Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. Journal of Biological Chemistry, 279(25), 26475–26480. doi: 10.1074/jbc.M313973200 [DOI] [PubMed] [Google Scholar]
- Matthews BG, Roguljic H, Franceschetti T, Roeder E, Matic I, Vidovic I, … Kalajzic I (2016). Gene-expression analysis of cementoblasts and osteoblasts. J Periodontal Res, 51(3), 304–312. doi: 10.1111/jre.12309 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nazarenko I, Lowe B, Darfler M, Ikonomi P, Schuster D, & Rashtchian A (2002). Multiplex quantitative PCR using self-quenched primers labeled with a single fluorophore. Nucleic Acids Research, 30(9), e37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nazarenko I, Pires R, Lowe B, Obaidy M, & Rashtchian A (2002). Effect of primary and secondary structure of oligodeoxyribonucleotides on the fluorescent properties of conjugated dyes. Nucleic Acids Research, 30(9), 2089–2195. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Okamura H, Aramburu J, Garcia-Rodriguez C, Viola JP, Raghavan A, Tahiliani M, … Rao A (2000). Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Molecular Cell, 6(3), 539–550. [DOI] [PubMed] [Google Scholar]
- Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, … Recker RR (1987). Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. Journal of Bone and Mineral Research, 2(6), 595–610. [DOI] [PubMed] [Google Scholar]
- Ranger AM, Gerstenfeld LC, Wang J, Kon T, Bae H, Gravallese EM, … Glimcher LH (2000). The nuclear factor of activated T cells (NFAT) transcription factor NFATp (NFATc2) is a repressor of chondrogenesis. Journal of Experimental Medicine, 191(1), 9–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ranger AM, Grusby MJ, Hodge MR, Gravallese EM, de la Brousse FC, Hoey T, … Glimcher LH (1998). The transcription factor NF-ATc is essential for cardiac valve formation. Nature, 392(6672), 186–190. [DOI] [PubMed] [Google Scholar]
- Rodova M, Lu Q, Li Y, Woodbury BG, Crist JD, Gardner BM, … Wang J (2011). Nfat1 regulates adult articular chondrocyte function through its age-dependent expression mediated by epigenetic histone methylation. Journal of Bone and Mineral Research, 26(8), 1974–1986. doi: 10.1002/jbmr.397 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sitara D, & Aliprantis AO (2010). Transcriptional regulation of bone and joint remodeling by NFAT. Immunological Reviews, 233(1), 286–300. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sun L, Blair HC, Peng Y, Zaidi N, Adebanjo OA, Wu XB, … Zaidi M (2005). Calcineurin regulates bone formation by the osteoblast. Proceedings of the National Academy of Sciences of the United States of America, 102(47), 17130–17135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, … Taniguchi T (2002). Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell, 3(6), 889–901. [DOI] [PubMed] [Google Scholar]
- Winslow MM, Pan M, Starbuck M, Gallo EM, Deng L, Karsenty G, & Crabtree GR (2006). Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Developmental Cell, 10(6), 771–782. [DOI] [PubMed] [Google Scholar]
- Yeo H, Beck LH, Thompson SR, Farach-Carson MC, McDonald JM, Clemens TL, & Zayzafoon M (2007). Conditional disruption of calcineurin B1 in osteoblasts increases bone formation and reduces bone resorption. Journal of Biological Chemistry, 282(48), 35318–35327. [DOI] [PubMed] [Google Scholar]
- Yu J, Zanotti S, Schilling L, & Canalis E (2018). Nuclear factor of activated T cells 2 is required for osteoclast differentiation and function in vitro but not in vivo. Journal of Cellular Biochemistry, 119(11), 9334–9345. doi: 10.1002/jcb.27212 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zanotti S, & Canalis E (2013). Notch suppresses nuclear factor of activated T cells (Nfat) transactivation and Nfatc1 expression in chondrocytes. Endocrinology, 154(2), 762–772. doi:en.2012–1925 [pii]; 10.1210/en.2012-1925 [doi] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zanotti S, & Canalis E (2015). Activation of Nfatc2 in Osteoblasts Causes Osteopenia. Journal of Cellular Physiology, 230(7), 1689–1695. doi: 10.1002/jcp.24928 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zanotti S, Kalajzic I, Aguila HL, & Canalis E (2014). Sex and genetic factors determine osteoblastic differentiation potential of murine bone marrow stromal cells. PLoS One, 9(1), e86757. doi: 10.1371/journal.pone.0086757 [doi];PONE-D-13–31354 [pii] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zanotti S, Smerdel-Ramoya A, & Canalis E (2011). Reciprocal regulation of Notch and nuclear factor of activated T-cells (NFAT) c1 transactivation in osteoblasts. Journal of Biological Chemistry, 286(6), 4576–4588. doi: 10.1074/jbc.M110.161893 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zanotti S, Smerdel-Ramoya A, & Canalis E (2013). Nuclear Factor of Activated T-cells (Nfat)c2 Inhibits Notch Signaling in Osteoblasts. Journal of Biological Chemistry, 288(1), 624–632. doi:M112.340455 [pii]; 10.1074/jbc.M112.340455 [doi] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zanotti S, Yu J, Bridgewater D, Wolf JM, & Canalis E (2018). Mice harboring a Hajdu Cheney Syndrome mutation are sensitized to osteoarthritis. Bone, 114, 198–205. doi: 10.1016/j.bone.2018.06.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, … Clemens TL (2002). Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. Journal of Biological Chemistry, 277(46), 44005–44012. [DOI] [PubMed] [Google Scholar]